Dr Nayak on Findings From the PROSPECT Trial of Tirabrutinib in Relapsed/Refractory PCNSL

"The earliest response was obtained at 1 month. This is very important for our relapsed/refractory patient population, because these patients are progressing neurologically and declining neurologically quite quickly."

Lakshmi Nayak, MD, director, Center for Central Nervous System (CNS) Lymphoma, senior physician, Dana-Farber Cancer Institute; and associate professor, neurology, Harvard Medical School, shared efficacy and safety data from the phase 2 PROSPECT trial (NCT04947319), which evaluated the second-generation BTK inhibitor tirabrutinib (Velexbru) in primary central nervous system lymphoma (PCNSL).

Findings presented at the 2025 Society for Neuro-Oncology Annual Meeting demonstrated strong efficacy with tirabrutinib, Nayak reported. At a data cutoff of November 1, 2024, and a median follow-up of 11.5 months, the overall response rate was 67%, including a complete response rate of 44%.

Nayak also emphasized the importance of the rapid onset of responses observed in the trial, noting that the earliest response with tirabrutinib was obtained at 1 month. This is considered a critical advantage with the drug for this patient population, as patients with relapsed/refractory disease often experience rapid neurological progression and decline, she said.

Moreover, the regimen demonstrated robust durability of response; the median duration of response was 9.3 months, and the median time to response was 1.0 month. The median progression-free survival (PFS) was 6 months, and the median overall survival was not reached, Nayak added.

Overall, the efficacy signal with tirabrutinib as monotherapy in this difficult-to-treat setting is considered very good, with both robust durability and favorable median PFS, Nayak emphasized. Regarding safety, the drug was very well tolerated with limited adverse effects, all of which were quite manageable, she stated.

Lakshmi Nayak, MD, is the director of the Center for Central Nervous System Lymphoma and a senior physician at Dana-Farber Cancer Institute. She is also an associate professor of neurology at Harvard Medical School.

Dr Lombardi on Phase 1 Data With Regorafenib Plus Temozolomide and CRT for Newly Diagnosed Glioblastoma

 TEAEs, including decreased neutrophil count (14.3%) and decreased platelet count (28.6%). Crucially, no patients discontinued treatment due to TEAEs, and all patients completed the DLT evaluation.

Accordingly, the recommended combinatory dose (RCD) was established as 40 mg of vorasidenib administered daily, combined with a standard dose of temozolomide, de la Fuente shared. This dose combination is currently being evaluated in the phase 2 portion of the study. Researchers expressed excitement over the safety profile, as this is the first time this specific combination has been studied in 

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Society for Neuro-Oncology Annual Meeting

Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.


